Drug giant Lilly backs Cambridge's Dicerna in $200M deal By: Boston Business Journal via Business Journals October 29, 2018 at 06:00 AM EDT The Cambridge biotech is eligible to earn up to $3.7 billion through the deal, with $200 million upfront. Read More >>
